Nasdaq:US$15.81 (+0.12) | HKEX:HK$24.95 (+0.00) | AIM:£2.29 (-0.01)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 8 Apr 2024

HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior antitumor activity to daratumumab in preclinical B-cell malignancies models